The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss

Myeloma Clinical Trial

— LOOMIS  

Official title:

The Development and Pilot Testing of a New Magnetic Resonance (MR) Imaging Protocol to Quantify Both Myeloma Disease Burden and Associated Bone Loss

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03951220
• Other study ID #: 12548
• Status: Completed
• Start date: March 29, 2018
• Est. completion date: December 30, 2020

Study information

• Verified date: May 2020
• Source: Oxford University Hospitals NHS Trust
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In the proposed study, the investigators will aim to develop and pilot a Magnetic Resonance (MR) imaging protocol and assess its ability to achieve the following: quantification of tumour burden and bone loss, detecting longitudinal changes in tumour load with therapy and detecting longitudinal changes in microarchitecture with therapy. The investigators also aim to investigate whether bone loss is better, worse or the same with different imaging techniques. This will be investigated by correlating the DXA imaging data with Diffusion-Weighted Magnetic Resonance Imaging (DWMRI) to see if it is possible to achieve quantifiable data of bone density.

Description:

In the proposed study, the investigators will aim to develop and pilot a Magnetic Resonance (MR) imaging protocol and assess its ability to achieve the following: quantification of tumour burden and bone loss, detecting longitudinal changes in tumour load with therapy and detecting longitudinal changes in microarchitecture with therapy. The investigators also aim to investigate whether bone loss is better, worse or the same with different imaging techniques. This will be investigated by correlating the DXA imaging data with Diffusion-Weighted Magnetic Resonance Imaging (DWMRI) to see if it is possible to achieve quantifiable data of bone density. Using the expertise of the Oxford Centre For Clinical Magnetic Resonance Research (OCMR) for imaging protocol development, and the new Fine Structural Analysis (FSA, Osteotronix Ltd, formerly Acuitas Medical) bone density quantification MRI method (Rafferty et al 2016), the investigators will test a single protocol which combines three emerging experimental imaging sequences into a simple, non-invasive whole body imaging protocol to quantify disease burden and bone disease. This has never been done before; if shown to be feasible, such a method would have two important applications: to precisely guide commissioned therapies in the clinic, so improving patient management; and as an exciting, novel research tool for the longitudinal combined assessment of tumour burden and cancer-induced bone disease in response to therapy. The investigators hypothesize that this imaging tool will be superior to the combined current standard-of-care investigations in the quantification of tumour burden and bone loss. There are currently no tools available for quantifying structural changes to bone and overall bone loss in myeloma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 67
• Est. completion date: December 30, 2020
• Est. primary completion date: December 30, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion Criteria (All Groups):

• Participant is able to and willing to give informed consent for participation in the study.
• Male or Female, aged 18 years or above.

Inclusion Criteria (Groups 1 and 2):

• Newly diagnosed myeloma or newly relapsed myeloma eligible for next therapy.
• Smouldering myeloma or intermediate or high risk MGUS.
• Patients attending Oxford NHS Haematology-Oncology centre.
• Diagnoses of MGUS, Smouldering Myeloma and MM made in accordance with the clinical diagnostic criteria set forth by IMWG (International Myeloma Working Group).

Exclusion Criteria (All Groups):

• Those who are unable or unwilling to give informed consent.
• Women who may be pregnant, breast feeding or women of child-bearing potential who are unwilling or unable to take sufficient precautionary measures will be excluded due to DXA imaging.

Exclusion Criteria (Groups 1 and 2):

• Signs of Spinal Cord Compression.
• Patients with documented metastatic lesions from another type of malignancy.
• Known contraindication for a MRI scan, including unacceptable pain on lying flat for 1 hour.

Related Conditions & MeSH terms

• Monoclonal Gammopathy of Undetermined Significance
• Monoclonal Gammopathy of Undetermined Significance (MGUS)
• Multiple Myeloma
• Myeloma
• Neoplasms, Plasma Cell
• Paraproteinemias
• Smoldering Multiple Myeloma
• Smouldering Myeloma

Intervention

Other:
• Diffusion Weighted Magnetic Resonance Imaging (DWMRI)
Using the expertise of the Oxford Centre For Clinical Magnetic Resonance Research (OCMR) for imaging protocol development, and the new Fine Structural Analysis (FSA, Osteotronix Ltd, formerly Acuitas Medical) bone density quantification MRI method (Rafferty et al 2016), we will test a single protocol which combines three emerging experimental imaging sequences into a simple, non-invasive whole body imaging protocol to quantify disease burden and bone disease. To our knowledge, this has never been done before; if shown to be feasible, such a method would have two important applications: to precisely guide commissioned therapies in the clinic, so improving patient management; and as an exciting, novel research tool for the longitudinal combined assessment of tumour burden and cancer-induced bone disease in response to therapy.
• DXA scan
Used to assess bone density
• Bloods and urine
Samples will be taken to assess bone biomarkers

Locations

Country	Name	City	State
United Kingdom	Churchill Hospital	Oxford	Oxfordshire

Sponsors (2)

Lead Sponsor	Collaborator
Oxford University Hospitals NHS Trust	Amgen

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	1. DW-MRI: ADC change	This will be calculated using the DW-MRI scans at both baseline and follow up	At baseline and six months
Primary	2. Total spinal 'hole' volume	This will be calculated using the DW-MRI scans at both baseline and follow up 3. Total spine 'collapse' volume 4. FSA: trabecular wall thickness (Rafferty et al, 2016)	At baseline and six months
Primary	3. Total spine 'collapse' volume	This will be calculated using the DW-MRI scans at both baseline and follow up	At baseline and six months
Primary	4. FSA: trabecular wall thickness	This will be calculated using the DW-MRI scans at both baseline and follow up	At baseline and six months
Secondary	Detect longitudinal changes in tumour load with therapy	All imaging will be repeated at 6 months. The scans will be analysed to see the difference in number of tumour sites before and after therapy (at baseline and at six months). Scans at both time points will be compared to see the difference in ADC, total spinal 'hole' volume, total spine 'collapse' volume and the trabecular wall thickness.	At 6 months
Secondary	Assess participants Quality of Life (EQ-5D) throughout the study	Assess participants Quality of Life (EQ-5D) throughout the study life using data from the EQ-5D-5L questionnaire.; The EQ-5D assess the mobility, self-care, usual activities, pain/discomfort, anxiety and depression via 3 options ranging from 'no problems' to 'unable to do/extreme pain/anxious'. The second part of the EQ-5D assess health on a scale where 100 is the best and 0 is the worst.	At baseline and six months
Secondary	Assess participants experience of the novel MR imaging scan	Analyse participants experience of the novel MR imaging using data from MRI/DXA scanning questionnaire.; This questionnaire assesses the experience of the novel imaging scan, whether any pain/discomfort was experienced. These answers are recorded on a 5 point likert scale where the lower number represents a better outcome.	At baseline and six months